Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia.
Research published in The Lancet shows that the PHiD-CV10 vaccine is highly effective at protecting children against invasive pneumococcal disease.
A new conjugate vaccine is highly effective (93–100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online First in The Lancet.
When infected with influenza, the body becomes an easy target for bacteria. The flu virus alters the host's immune system and compromises its capacity to effectively fight off bacterial infections. Now, a team of immunologists at the Helmholtz Centre for Infection Research (HZI) and cooperation partners has discovered that an immune system molecule called TLR7 is partly to blame. The molecule recognizes the viral genome - and then signals scavenger cells of the immune system to ingest fewer bacteria.
Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.
Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.
Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.
A University of Nottingham expert has been awarded -80,000 by two national charities to study the impact of gluten intolerance on patients in the UK.
Patients with invasive pneumococcal disease who have the FcyRIIa-R/R131 polymorphism may have better survival outcomes than those without the genotype, suggest study findings.
Bacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe bacterial meningitis. Recently, researchers at the University of Adelaide in Australia sought to identify new vaccine targets in Streptococcus pneumoniae, which is the most common cause of bacterial meningitis in the world.
Anirban Chatterjee, chief of health and nutrition for UNICEF in Ghana, said the country "is doing a lot" to fight child mortality -- referring to a recently launched vaccination campaign and an initiative to educate mothers about nutrition -- but "I don't think it's enough" to reach the fourth U.N. Millennium Development Goal (MDG) to reduce the under-five mortality rate by two thirds by 2015, Inter Press Service reports.
In this post in PSI's "Healthy Lives" blog, Deputy Editor Tom Murphy examines routine vaccination solutions in Nigeria, where "the Decade of Vaccines Economics projects 90 percent vaccine coverage against Hib, pneumococcal disease, rotavirus, measles and pertussis can save 600,000 lives and $17 billion in Nigeria over the next 10 years."
The vaccine given to children to immunise against serious pneumococcal disease does not offer full protection, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, finding that the number of cases diagnosed has tripled over the past 50 years.
"Starting this week, Ghana will vaccinate the first babies in a new campaign against rotavirus -- a cause of severe diarrhea -- and pneumococcal disease, which causes pneumonia, meningitis and sepsis," Reuters reports.
Ghana has become the first African country to introduce pneumococcal and rotavirus vaccines at the same time, simultaneously tackling the leading causes of the world’s two biggest childhood killers – pneumonia and diarrhoea.
The number of deaths from measles fell about 74 percent between 2000 and 2010, from slightly more than 535,000 in 2000 to an estimated 139,200 people worldwide in 2010, "missing an internationally agreed target for a 90 percent fall mainly because of low vaccine coverage in India and Africa where the virus kills tens of thousands a year," Reuters reports.
A study released today by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health has identified the most feasible and impactful solutions for Nigeria's immunization program that could offer the best hope yet for scaling up vaccine access to the nation's most rural areas and taking aim at the country's precipitous number of child deaths.
Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.
Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.
Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail. The study, published today in Nature Genetics, which investigates how bacteria change their disguise to evade the vaccines, has implications for how future vaccines can be made more effective.